Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 28 Neoplasms 13 Colonic Neoplasms 12 Breast Neoplasms 12 Prostatic Neoplasms 9 Polycythemia Vera 9 Venous Thromboembolism 8 Multiple Myeloma 8 Recurrence 6 Carcinoma, Non-Small-Cell Lung 6 Rectal Neoplasms 5 Thrombocythemia, Essential 4 Ovarian Neoplasms 4 Neoplasms, Plasma Cell 4 Neoplasm Metastasis 4 Myeloproliferative Disorders 4 Esophageal Neoplasms 4 Cardiovascular Diseases 4 Barrett Esophagus 4 Stomach Neoplasms 3 Precancerous Conditions 3 Melanoma 3 Lung Neoplasms 3 Gastrointestinal Neoplasms 3 Adenomatous Polyps 3 Adenoma 3 Tobacco Use Disorder 2 Thrombosis 2 Thromboembolism 2 Smoking Cessation 2

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 11 aflutinib 9 Drug Therapy 9 Gefitinib 8 Radiotherapy 6 Docetaxel 6 Cisplatin 6 pembrolizumab 5 anlotinib 5 Radiosurgery 5 Paclitaxel 5 icotinib 4 Vinorelbine 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 camrelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × Aspirin × Clear all

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡